ClinicalTrials.gg
CompletedNCT05425719Updated Apr 18, 2024Results posted

Pharmacokinetics and Safety of MB-102 (Relmapirazin) and the MediBeacon Transdermal GFR Measurement System in Evaluation of Kidney Function in Normal and Renal Compromised Subjects

A Phase 3 interventional study of MB-102 and MediBeacon Transdermal Glomerular Filtration Rate Measurement System (TGFR) in Chronic Kidney Disease, sponsored by MediBeacon. Completed at 8 sites in 2 countries. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-04-18.

Sponsored by MediBeacon · Phase 3, Interventional, and Other

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
249
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 988 studies in Renal Insufficiency, Chronic with a site in United States — 170 open to participants now, 218 under way, 25 of them phase 3. Renal Insufficiency, Chronic · United States.

Enrollment
187th of 819
249 · median 72
Started
2022
with 56 others
Phase 3
147 of 988
13 open now
Registered
752nd of 988
by date

Among the 988 studies in Renal Insufficiency, Chronic with a site in United States, this one is the 187th largest by enrollment of the 819 interventional ones that give a count, is one of 57 that started in 2022, is one of 147 in phase 3, and was the 752nd registered.

Renal Insufficiency, Chronic

3,096 studies on the registry are indexed under Renal Insufficiency, Chronic; 701 are open to participants now.

Browse Renal Insufficiency, Chronic studies →

Open to participants now

170 of the 988 studies in Renal Insufficiency, Chronic with a site in United States are open now. Recruiting first, the newest first:

165 more — sign in →

All 170 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 434 Renal Insufficiency, Chronic studies recruiting now, 244 (56%) set no upper age limit and 110 (25%) stop at 75 or younger; 44 take children under 18; 80 take healthy volunteers.

This study: 18 Years and older · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 988 studies in Renal Insufficiency, Chronic with a site in United States, or all of them as a file.
02

Study summary

The goal of this clinical trial was to compare transdermal glomerular filtration rate (tGFR) to plasma-derived indexed (to body surface area; BSA) GFR (nGFR) using MB-102 (relmapirazin) as the fluorescent compound. Adults with kidney function ranging from normal to Stage 4 chronic kidney disease (CKD) and participants spanning the entire range of human skin colors as defined by the Fitzpatrick Skin Scale (FSS) were included in the study.

The main questions that the study aimed to answer were:

  • To establish that the MB-102 transdermal fluorescence measured GFR using the MediBeacon Transdermal GFR Measurement System is comparable to the measured MB-102 plasma GFR
  • To evaluate the safety and tolerability of a single dose of MB-102 in study participants
  • To evaluate the safety and effectiveness of the MediBeacon Transdermal GFR Measurement System (TGFR) for the non-invasive transdermal fluorescence detection of MB-102 in participants

Participants had a transdermal sensor placed on their upper chest, and the TGFR collected background fluorescence. Participants then received a single dose of MB-102. Blood samples were collected and fluorescent measurements were taken over a 12- to 24-hour period. Following completion of the treatment period, participants returned to the study center approximately 1 week later for a safety follow-up visit. Researchers compared the results to see if the transdermal GFR measurements were comparable to the measured plasma GFR in those with and without normal kidney function and different skin coloration.

03

Conditions studied

  • Chronic Kidney Disease

Keywords

  • Glomerular Filtration Rate
  • Transdermal fluorescence detection
  • Relmapirazin
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Eligible female non-pregnant participants who are either not of or willing to use adequate during the trial
  • Males must be willing to practice abstinence or utilize adequate contraception from dosing day to at least 7 days post-dose
  • For women of child-bearing potential, the participant should have a negative serum pregnancy test at screening, and agrees to one of the following acceptable contraceptive methods used consistently and correctly i.e. abstinence, oral contraceptive either combined or progesterone alone; injectable progesterone, implants of levonorgestrel, estrogenic vaginal ring, percutaneous contraceptive patches, IUD device or system or male partner sterilization
  • Men will not donate sperm during the study and for 1 month following the last dose of study drug
  • Participants who are capable of directly providing and who can comply with the requirements and restrictions required by the protocol
  • Adequate venous access sufficient to allow blood sampling per protocol requirements

Exclusion criteria

Exclusion Criteria:

  • Participants positive via PCR testing for COVID-19 (Vaccinated participants without symptoms of COVID-19 are not required to undergo PCR testing but may be tested at the discretion of the study site)
  • Recent donation or loss of blood or plasma: 100 mL to 499 mL within 30 days prior to the initial dose of the study medication; or more than 499 mL within 56 days prior to the initial dose of study medication
  • Non-steroidal anti-inflammatory (NSAID) use within 3 days of MB-102 dosing
  • Participant has participated in a clinical trial and has received an product within the following time ranges: prior to the first dosing day in the current study: either 30 days or 5 half-lives of the investigational product (whichever duration is longer)
  • History of skin sensitivity to adhesives (e.g. Band-Aids, surgical tape)
  • History of severe allergic reactions (unacceptable adverse events) or anaphylactoid reaction to any allergen including drugs, MB-102 or other related products (intolerance to a drug is not considered a drug allergy).
  • Any characteristics which, in the opinion of the investigator, makes the participant a poor candidate for participation in the clinical trial
  • Significant scarring, tattoos or alterations in pigmentation on the sternum or other sensor location testing areas that would alter sensor readings versus other areas of the skin
  • Any serious or uncontrolled medical disorder, active infection, physical exam finding, laboratory finding, or psychiatric condition that in the opinion of the investigator would limit the participant's ability to complete study requirements or may put the participant at increased risk or compromise the interpretability of study results.
  • Currently receiving dialysis
  • Currently anuric
  • Positive serum pregnancy test
  • Participants with an > 120 mL/min/1.73m\^2
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

05

Study design

Phase
Phase 3
Primary purpose
Other
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
249 participants (actual)

Study arms

  • Experimental
    eGFR ≥ 70 mL/min/1.73 m^2

    Participants with eGFR ≥ 70 mL/min/1.73 m\^2 received one 130 mg dose of MB-102 and a transdermal sensor was placed on their chest. Blood samples and fluorescent measurements were collected over 12 hours.

    Drug: MB-102 · Device: MediBeacon Transdermal Glomerular Filtration Rate Measurement System (TGFR)

  • Experimental
    eGFR < 70 mL/min/1.73 m^2

    Participants with eGFR \< 70 mL/min/1.73 m\^2 received one 130 mg dose of MB-102 and a transdermal sensor was placed on their chest. Blood samples and fluorescent measurements were collected over 24 hours.

    Drug: MB-102 · Device: MediBeacon Transdermal Glomerular Filtration Rate Measurement System (TGFR)

Interventions

  • DrugMB-102

    18.6 mg/mL in a 7.0 mL volume administered by intravenous injection over 30 - 60 seconds, followed by a 10 mL normal saline flush administered intravenously over 30 - 60 seconds

    Also known as: Relmapirazin

  • DeviceMediBeacon Transdermal Glomerular Filtration Rate Measurement System (TGFR)

    On treatment day, participants had a transdermal sensor placed on their upper chest, and the MediBeacon Transdermal GFR Measurement System was initiated to collect background fluorescence. After collection of background fluorescence, participants received a single dose of MB-102.

06

What researchers measure

Primary outcomes

  1. Proportion of Transdermal Derived Glomerular Filtration Rate (tGFR) Values Within 30% of the nGFR Plasma-derived Indexed Glomerular Filtration Rate (nGFR) Values

    The performance measure of P30 is defined as the proportion of transdermal derived GFR values that are within 30% of the measured plasma-derived GFR. The comparison of transdermal derived glomerular filtration rate (tGFR) with respect to the plasma-derived indexed glomerular filtration rate (nGFR) was calculated with a double-sided 95% confidence interval (CI). The performance goal was 0.85, and success for the study was defined as a lower limit of the 95% CI greater than 0.85.

    Time frame: Up to 24 hours following the study dose

Secondary outcomes

  1. Number of Participants With Treatment-emergent Adverse Events Associated With MB-102 Administration

    An adverse event is defined as any untoward medical occurrence, unintended disease or injury, or untoward clinical signs (including abnormal laboratory findings) in subjects, temporally associated with the use of a medicinal product, whether or not related to the investigational medical device or drug.

    Time frame: From the time of dosing through the follow-up visit, up to 10 days

  2. Number of Participants With Treatment-emergent Adverse Events Associated With the MediBeacon Transdermal GFR Measurement System Device

    An adverse event is defined as any untoward medical occurrence, unintended disease or injury, or untoward clinical signs (including abnormal laboratory findings) in subjects, temporally associated with the use of a medicinal product, whether or not related to the investigational medical device or drug.

    Time frame: From the time of dosing through the follow-up visit, up to 10 days

07

Results

Posted Apr 18, 2024

Participant flow

Participant flow — Overall Study
MilestoneeGFR ≥ 70 mL/Min/1.73 m^2eGFR < 70 mL/Min/1.73 m^2
Started130119
Completed125118
Not completed51
Withdrew: Lost to follow-up40
Withdrew: Withdrew consent11

Outcome measures

PrimaryProportion of Transdermal Derived Glomerular Filtration Rate (tGFR) Values Within 30% of the nGFR Plasma-derived Indexed Glomerular Filtration Rate (nGFR) Values

The performance measure of P30 is defined as the proportion of transdermal derived GFR values that are within 30% of the measured plasma-derived GFR. The comparison of transdermal derived glomerular filtration rate (tGFR) with respect to the plasma-derived indexed glomerular filtration rate (nGFR) was calculated with a double-sided 95% confidence interval (CI). The performance goal was 0.85, and success for the study was defined as a lower limit of the 95% CI greater than 0.85.

Time frame:
Up to 24 hours following the study dose
Reported as:
Number · Proportion of tGFR within 30% of nGFR
Proportion of Transdermal Derived Glomerular Filtration Rate (tGFR) Values Within 30% of the nGFR Plasma-derived Indexed Glomerular Filtration Rate (nGFR) Values
Proportion of tGFR within 30% of nGFReGFR ≥ 70 mL/Min/1.73 m^2eGFR < 70 mL/Min/1.73 m^2All Participants
Proportion of Transdermal Derived Glomerular Filtration Rate (tGFR) Values Within 30% of the nGFR Plasma-derived Indexed Glomerular Filtration Rate (nGFR) Values0.96 (0.89 to 0.99)0.92 (0.85 to 0.97)0.94 (0.89 to 0.97)
SecondaryNumber of Participants With Treatment-emergent Adverse Events Associated With MB-102 Administration

An adverse event is defined as any untoward medical occurrence, unintended disease or injury, or untoward clinical signs (including abnormal laboratory findings) in subjects, temporally associated with the use of a medicinal product, whether or not related to the investigational medical device or drug.

Time frame:
From the time of dosing through the follow-up visit, up to 10 days
Reported as:
Count of participants · Participants
Number of Participants With Treatment-emergent Adverse Events Associated With MB-102 Administration
ParticipantseGFR ≥ 70 mL/Min/1.73 m^2eGFR < 70 mL/Min/1.73 m^2
Number of Participants With Treatment-emergent Adverse Events Associated With MB-102 Administration10
SecondaryNumber of Participants With Treatment-emergent Adverse Events Associated With the MediBeacon Transdermal GFR Measurement System Device

An adverse event is defined as any untoward medical occurrence, unintended disease or injury, or untoward clinical signs (including abnormal laboratory findings) in subjects, temporally associated with the use of a medicinal product, whether or not related to the investigational medical device or drug.

Time frame:
From the time of dosing through the follow-up visit, up to 10 days
Reported as:
Count of participants · Participants
Number of Participants With Treatment-emergent Adverse Events Associated With the MediBeacon Transdermal GFR Measurement System Device
ParticipantseGFR ≥ 70 mL/Min/1.73 m^2eGFR < 70 mL/Min/1.73 m^2
Number of Participants With Treatment-emergent Adverse Events Associated With the MediBeacon Transdermal GFR Measurement System Device00

Adverse events

Collected over Treatment-emergent adverse events were collected from the time of dosing through the follow-up visit, up to 10 days. Non-serious events are listed at a 1% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
eGFR ≥ 70 mL/Min/1.73 m^20/130 (0%)0/130 (0%)3/130 (2.3%)
eGFR < 70 mL/Min/1.73 m^20/119 (0%)0/119 (0%)7/119 (5.9%)
Most frequent other events
Most frequent other events
EventeGFR ≥ 70 mL/Min/1.73 m^2eGFR < 70 mL/Min/1.73 m^2
HeadacheNervous system disorders3/1301/119
Cardiac murmurInvestigations0/1302/119
EcchymosisSkin and subcutaneous tissue disorders0/1302/119
HypertensionVascular disorders0/1302/119

Baseline characteristics

Safety Population: all subjects who enrolled in the study and were dosed with MB-102

Age, Continuous
Age, Continuous(years)eGFR ≥ 70 mL/Min/1.73 m^2eGFR < 70 mL/Min/1.73 m^2Total
Mean46.9 ± 14.1961.5 ± 13.4553.9 ± 15.63
Sex: Female, Male
Sex: Female, Male(Participants)eGFR ≥ 70 mL/Min/1.73 m^2eGFR < 70 mL/Min/1.73 m^2Total
Female6245107
Male6874142
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)eGFR ≥ 70 mL/Min/1.73 m^2eGFR < 70 mL/Min/1.73 m^2Total
Hispanic or Latino361450
Not Hispanic or Latino94103197
Unknown or Not Reported022
Race (NIH/OMB)
Race (NIH/OMB)(Participants)eGFR ≥ 70 mL/Min/1.73 m^2eGFR < 70 mL/Min/1.73 m^2Total
American Indian or Alaska Native202
Asian372764
Native Hawaiian or Other Pacific Islander000
Black or African American334376
White5849107
More than one race000
Unknown or Not Reported000
08

Study locations

8 sites
  • Velocity Clinical Research
    Edgewater, Florida 32132, United States
  • Research by Design, LLC
    Chicago, Illinois 60643, United States
  • Nucleus Network
    Saint Paul, Minnesota 55114, United States
  • Carolina Phase I Research
    Raleigh, North Carolina 27612, United States
  • Endeavor Clinical Trials, LLC
    San Antonio, Texas 78240, United States
  • West China Hospital of Sichuan University
    Chengdu, Sichuan 610093, China
  • Peking University First Hospital
    Beijing, 100034, China
  • Affiliated Hospital of Xuzhou Medical University
    Xuzhou, 2210029, China
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jun 2022 to primary completion in Feb 2023, 8 months.

Results were first posted in Apr 2024, 1 year 2 months after primary completion.

Of 104 industry-sponsored phase 3 interventional studies under Renal Insufficiency, Chronic, half reached primary completion within 29 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 49. This study's 8 months is below that.

Counting every sponsor, half of 145 studies reached it within 32 months; a quarter within 19 and three quarters within 54.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 21, 2022
First posted
Jun 21, 2022
StartActual
Jun 14, 2022
Primary completionActual
Feb 15, 2023
CompletionActual
Feb 15, 2023
Results first posted
Apr 18, 2024
Last update
Apr 18, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 18, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT05425719
Lead sponsor
MediBeacon
Responsible party
Sponsor
First posted
Jun 21, 2022
Start date
Jun 14, 2022
Primary completion
Feb 15, 2023
Completion
Feb 15, 2023
Results posted
Apr 18, 2024
Last update
Apr 18, 2024

Study contacts

Richard B Dorshow, PhD
study director · MediBeacon, Inc.

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Relmapirazin

Start the discussion